Bausch Health Q1 2026: A GAAP Loss, Non-GAAP Momentum, and a Quiet Confidence in the 2026 Revenue Forecast

Executive snapshot

The Bausch Health Companies Inc. release for the first quarter of 2026 shows a mixed-but-meaningful picture for BHC investors. On the revenue line, the company posted $2.52 billion in consolidated revenues, up 12% from the year-ago period on a reported basis and up 7% on an organic (non-GAAP) basis.

GAAP numbers tell a bleaker tale: GAAP net loss attributable to Bausch Health was $1.423 billion and GAAP net loss totaled $1.431 billion, driven in large part by a $1.426 billion goodwill impairment charge. The company reports a GAAP loss per share of $(3.82) (basic and diluted), compared with $(0.16) in the prior year period.

On a non-GAAP basis, the picture brightens: adjusted earnings per diluted share (non-GAAP) came in at $0.78, and consolidated Adjusted EBITDA was $837 million, up 27% year over year.

The quarter marked the twelfth consecutive quarter of year-over-year revenue growth and Adjusted EBITDA growth, with 14% revenue growth (reported) and 9% organic growth, plus 17% growth in Adjusted EBITDA (non-GAAP). The company also generated $319 million in Adjusted Cash Flow from Operations (non-GAAP).

In plain terms: the GAAP numbers carry a heavy one-time impairment load, but the operating engine shows momentum when you strip out that non-cash charge. Management reaffirmed the full-year 2026 revenue, Adjusted EBITDA (non-GAAP), and Adjusted Cash Flow from Operations (non-GAAP) guidance.

What the numbers imply and how the story hangs together

First, the split personality is clear. GAAP results capture a large impairment hit—non-cash, non-operational in nature—that weighs on earnings per share and total net income. The $1.426 billion goodwill impairment, embedded in the quarter, helps explain why GAAP earnings looked materially negative even as the business generated robust cash flow and delivered organic revenue growth.

Second, the non-GAAP metrics tell a different story: a positive Adjusted EPS of $0.78 and an Adjusted EBITDA trajectory that’s up sharply year over year. For a company in a capital-intensive position and undergoing portfolio adjustments, that divergence between GAAP and non-GAAP performance isn’t an anomaly; it’s a feature of the ongoing debate between what the business actually earns from operations and how accounting labels those earnings for investors.

Third, the revenue trajectory remains a talking point. A 12% top-line gain on a reported basis, with 7% organic growth, plus 12-quarter streaks of growth on both revenue and Adjusted EBITDA, suggests a business that can scale in a refined portfolio. The question for investors isn’t just “What did you earn this quarter?” but “What can you sustain this year and beyond, given the mix of legacy assets and new structure?”

Finally, the reaffirmed guidance matters. With leadership backing the 2026 revenue, Adjusted EBITDA, and Adjusted Cash Flow from Operations targets, the market gets a signal that, despite the GAAP murkiness, the path to cash generation and margin discipline remains intact—an important distinction for peers watching the same balance-sheet discipline play out in a sector where impairment charges occasionally masquerade as strategic reshuffling.

Outlook for Bausch Health and sector peers

For the equity narrative, the quarter reinforces a familiar theme: investors should differentiate between GAAP and non-GAAP storytelling. The stock’s immediate reaction may hinge on where analysts land on the EPS consensus and how they weigh the impairment charge against the company’s cash-flow progress. In other words, this is a case study in earnings surprise—on an Adjusted EPS and cash-flow basis, not on GAAP net income alone.

From a sector perspective, several takeaways emerge. One, the ability to generate cash from operations while navigating impairment-related write-downs is a valuable attribute in a capital-heavy health-care portfolio. Two, the reaffirmation of the 2026 revenue forecast and Adjusted cash-flow targets suggests resilience in the underlying business model, even if a one-time accounting hit clouds near-term profitability. Three, peers with similar portfolios should monitor the balance between one-off charges and ongoing operating leverage, as investors increasingly treat non-GAAP metrics with the same scrutiny they apply to GAAP numbers.

In markets where “EPS” is often treated as a binary signal, this quarter reminds us that the direction of travel matters more than a single line item. If a rival company can parlay organic growth into sustained cash flow while carefully managing impairment exposure, the sector may see multiple names re-rate on fundamentals rather than accounting quirks.

Notes on GAAP vs non-GAAP and what to watch next

• GAAP net loss includes a nearly $1.426 billion goodwill impairment charge—non-cash and outside ongoing operations.
• Adjusted EPS (non-GAAP) of $0.78 and Adjusted EBITDA of $837 million signal underlying operating strength, though these figures are not comparable to GAAP metrics.
• Revenue of $2.52 billion marks a solid year-over-year improvement, with double-digit growth on the top line even as the bottom-line GAAP figure remains negative.
• The company reiterates its 2026 guidance for revenue, Adjusted EBITDA (non-GAAP), and Adjusted Cash Flow from Operations (non-GAAP), signaling confidence in the trajectory despite the impairment hit.
• Analysts will weigh the EPS consensus against the GAAP/Non-GAAP split and the implied longer-term margin profile as the year unfolds.